<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Hilhorst-Hofstee, Y.</title>
    <link>http://repub.eur.nl/res/aut/3789/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome (Article)</title>
      <link>http://repub.eur.nl/res/pub/35039/</link>
      <pubDate>2012-01-01T00:00:00Z</pubDate>
      <description>Background: Aneurysmseosteoarthritis syndrome (AOS) is a new autosomal dominant syndromic form of thoracic aortic aneurysms and dissections characterised by the presence of arterial aneurysms and tortuosity, mild craniofacial, skeletal and cutaneous anomalies, and early-onset osteoarthritis. AOS is caused by mutations in the SMAD3 gene. Methods: A cohort of 393 patients with aneurysms without mutation in FBN1, TGFBR1 and TGFBR2 was screened for mutations in SMAD3. The patients originated from The Netherlands, Belgium, Switzerland and USA. The clinical phenotype in a total of 45 patients from eight different AOS families with eight different SMAD3 mutations is described. In all patients with a SMAD3 mutation, clinical records were reviewed and extensive genetic, cardiovascular and orthopaedic examinations were performed. Results Five novel SMAD3 mutations (one nonsense, two missense and two frame-shift mutations) were identified in five new AOS families. A follow-up description of the three families with a SMAD3 mutation previously described by the authors was included. In the majority of patients, early-onset joint abnormalities, including osteoarthritis and osteochondritis dissecans, were the initial symptom for which medical advice was sought. Cardiovascular abnormalities were present in almost 90% of patients, and involved mainly aortic aneurysms and dissections. Aneurysms and tortuosity were found in the aorta and other arteries throughout the body, including intracranial arteries. Of the patients who first presented with joint abnormalities, 20% died suddenly from aortic dissection. The presence of mild craniofacial abnormalities including hypertelorism and abnormal uvula may aid the recognition of this syndrome. Conclusion: The authors provide further insight into the phenotype of AOS with SMAD3 mutations, and present recommendations for a clinical work-up.</description>
    </item> <item>
      <title>Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis (Article)</title>
      <link>http://repub.eur.nl/res/pub/31637/</link>
      <pubDate>2011-02-01T00:00:00Z</pubDate>
      <description>Thoracic aortic aneurysms and dissections are a main feature of connective tissue disorders, such as Marfan syndrome and Loeys-Dietz syndrome. We delineated a new syndrome presenting with aneurysms, dissections and tortuosity throughout the arterial tree in association with mild craniofacial features and skeletal and cutaneous anomalies. In contrast with other aneurysm syndromes, most of these affected individuals presented with early-onset osteoarthritis. We mapped the genetic locus to chromosome 15q22.2-24.2 and show that the disease is caused by mutations in SMAD3. This gene encodes a member of the TGF-β pathway that is essential for TGF-β signal transmission. SMAD3 mutations lead to increased aortic expression of several key players in the TGF-β pathway, including SMAD3. Molecular diagnosis will allow early and reliable identification of cases and relatives at risk for major cardiovascular complications. Our findings endorse the TGF-β pathway as the primary pharmacological target for the development of new treatments for aortic aneurysms and osteoarthritis. </description>
    </item> <item>
      <title>The clinical spectrum of complete FBN1 allele deletions (Article)</title>
      <link>http://repub.eur.nl/res/pub/21419/</link>
      <pubDate>2010-11-10T00:00:00Z</pubDate>
      <description>The most common mutations found in FBN1 are missense mutations (56%), mainly substituting or creating a cysteine in a cbEGF domain. Other mutations are frameshift, splice and nonsense mutations. There are only a few reports of patients with marfanoid features and a molecularly proven complete deletion of a FBN1 allele. We describe the clinical features of 10 patients with a complete FBN1 gene deletion. Seven patients fulfilled the Ghent criteria for Marfan syndrome (MFS). The other three patients were examined at a young age and did not (yet) present the full clinical picture of MFS yet. Ectopia lentis was present in at least two patients. Aortic root dilatation was present in 6 of the 10 patients. In three patients, the aortic root diameter was on the 95th percentile and in one patient, the diameter of the aortic root was normal, the cross-section, however, had a cloverleaf appearance. Two patients underwent aortic root surgery at a relatively young age (27 and 34 years). Mitral valve prolapse was present in 4 of the 10 patients, and billowing of the mitral valve in 1. All patients had facial and skeletal features of MFS. Two patients with a large deletion extending beyond the FBN1 gene had an extended phenotype. We conclude that complete loss of one FBN1 allele does not predict a mild phenotype, and these findings support the hypothesis that true haploinsufficiency can lead to the classical phenotype of Marfan syndrome.European Journal of Human Genetics advance online publication, 10 November 2010; doi:10.1038/ejhg.2010.174.</description>
    </item> <item>
      <title>Stickler syndrome caused by COL2A1 mutations: genotype-phenotype correlation in a series of 100 patients (Article)</title>
      <link>http://repub.eur.nl/res/pub/20001/</link>
      <pubDate>2010-08-01T00:00:00Z</pubDate>
      <description>Stickler syndrome is an autosomal dominant connective tissue disorder caused by mutations in different collagen genes. The aim of our study was to define more precisely the phenotype and genotype of Stickler syndrome type 1 by investigating a large series of patients with a heterozygous mutation in COL2A1. In 188 probands with the clinical diagnosis of Stickler syndrome, the COL2A1 gene was analyzed by either a mutation scanning technique or bidirectional fluorescent DNA sequencing. The effect of splice site alterations was investigated by analyzing mRNA. Multiplex ligation-dependent amplification analysis was used for the detection of intragenic deletions. We identified 77 different COL2A1 mutations in 100 affected individuals. Analysis of the splice site mutations showed unusual RNA isoforms, most of which contained a premature stop codon. Vitreous anomalies and retinal detachments were found more frequently in patients with a COL2A1 mutation compared with the mutation-negative group (P&lt;0.01). Overall, 20 of 23 sporadic patients with a COL2A1 mutation had either a cleft palate or retinal detachment with vitreous anomalies. The presence of vitreous anomalies, retinal tears or detachments, cleft palate and a positive family history were shown to be good indicators for a COL2A1 defect. In conclusion, we confirm that Stickler syndrome type 1 is predominantly caused by loss-of-function mutations in the COL2A1 gene as &gt;90% of the mutations were predicted to result in nonsense-mediated decay. On the basis of binary regression analysis, we developed a scoring system that may be useful when evaluating patients with Stickler syndrome.European Journal of Human Genetics advance online publication, 24 February 2010; doi:10.1038/ejhg.2010.23.</description>
    </item> <item>
      <title>Noninvasive test for fragile X syndrome, using hair root analysis (Article)</title>
      <link>http://repub.eur.nl/res/pub/9115/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>Identification of the FMR1 gene and the repeat-amplification mechanism
          causing fragile X syndrome led to development of reliable DNA-based
          diagnostic methods, including Southern blot hybridization and PCR. Both
          methods are performed on DNA isolated from peripheral blood cells and
          measure the repeat size in FMR1. Using an immunocytochemical technique on
          blood smears, we recently developed a novel test for identification of
          patients with fragile X syndrome. This method, also called "antibody
          test," uses monoclonal antibodies against the FMR1 gene product (FMRP) and
          is based on absence of FMRP in patients' cells. Here we describe a new
          diagnostic test to identify male patients with fragile X syndrome, on the
          basis of lack of FMRP in their hair roots. Expression of FMRP in hair
          roots was studied by use of an FMRP-specific antibody test, and the
          percentage of FMRP-expressing hair roots in controls and in male fragile X
          patients was determined. Control individuals showed clear expression of
          FMRP in nearly every hair root, whereas male fragile X patients lacked
          expression of FMRP in almost all their hair roots. Mentally retarded
          female patients with a full mutation showed FMRP expression in only some
          of their hair roots (&lt;55%), and no overlap with normal female controls was
          observed. The advantages of this test are (1) plucking of hair follicles
          does no appreciable harm to the mentally retarded patient, (2) hairs can
          be sent in a simple envelope to a diagnostic center, and (3) the result of
          the test is available within 5 h of plucking. In addition, this test
          enabled us to identify two fragile X patients who did not show the full
          mutation by analysis of DNA isolated from blood cells.</description>
    </item>
  </channel>
</rss>